Normal Glass Lining Expertise IPO Subscription Standing: The preliminary public providing (IPO) of Normal Glass Lining Expertise Ltd obtained a 58.35 instances subscription to date on the final bidding course of (January 8). The IPO obtained bids for 1,21,54,77,628 shares in opposition to a proposal of two,08,29,567 shares, in response to the BSE information.
Because the final rely (12:09 pm), the non-institutional investor (NII) class witnessed a subscription of 147.80 instances, whereas the retail particular person investor (RII) portion fetched 46.08 instances. The portion for certified institutional consumers (QIBs) noticed 10.96 instances subscription.
The Normal Glass Lining Expertise inventory will debut on the exchanges BSE and NSE on Monday, January 13, 2025.
Normal Glass Lining Expertise IPO Key Particulars
- Promoting shareholders by way of OFS: S2 Engineering Companies, Kandula Ramakrishna, Kandula Krishna Veni, Nageswara Rao Kandula, Normal Holdings, Katragadda Venkata Ramani, and Venkata Siva Prasad Katragadda.
- E-book-running Lead Managers (BRLMs): IIFL Capital Companies Ltd and Motilal Oswal Funding Advisors Ltd.
- Registrar: KFin Applied sciences.
What does Normal Glass Lining Expertise do?
Normal Glass Lining Expertise Ltd focuses on offering turnkey options for pharmaceutical and chemical producers, encompassing design, engineering, manufacturing, meeting, set up, and commissioning. Its purchasers embody main pharmaceutical firms like Aurobindo Pharma, Cadila Prescribed drugs, Granules India Ltd, Macleods Prescribed drugs, Piramal Pharma, and Suven Prescribed drugs.
